Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth

Inclusion criteria: 1. HIV perinatally infected 2. Know their HIV+ status 3. Initiated ART prior to 6 months of age 4. Male and female ≥ 9 years old 5. In generally good health 6. Plasma viral load \< 200 copies/ml on ART at screening 7. CD4 count above 400 cells/mm3 at screening 8. Participants of childbearing potential who are sexually active must be willing to practice effective contraception during the study 9. Negative urine β-HCG (human chorionic gonadotropin) pregnancy test for any female of childbearing age (post-menarche) 10. Availability for follow-up for planned duration of the study 11. Passing a test of understanding is required for participants ≥ 18 years old or the parent(s)/legal representative of participants \< 18 years old before consent. 12. Written informed consent from participants ≥ 18 years old or parent(s)/legal representative of participants \< 18 years old. Assent by participants aged 9-17 years old will also be required. 13. Laboratory criteria within 8 weeks prior to enrollment * Hb \>11.0 g/dl * White blood cell count \>3000 cells/mm3 * Platelets \>125,000/ mm3 * ALT \<1.5 x upper limit of normal * Creatinine \<1.5 x upper limit of normal Exclusion criteria: 1. Participants who experienced virological failure necessitating ART modifications 2. Participants who had ART interruption that lasted \>2 weeks 3. Prior or current pancreatitis or history of alcohol abuse. 4. Systemic cortisone treatment within the past 30 days 5. Participants coinfected with chronic hepatitis B (Hepatitis B surface antigen, HBsAg+) or hepatitis C (Hepatitis C antibody, HCV Ab+) at screening 6. Participants with signs of autoimmune diseases 7. Participants with history of myocarditis 8. Participants on any immune modulating or investigational drug 9. Pregnant or breastfeeding female